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Sudden cardiac death (SCD) remains a daunting problem. It is a major public health issue for several reasons: from its prevalence (20% of total
mortality in the industrialized world) to the devastating psycho-social impact on society and on the families of victims often still in their prime,
and it represents a challenge for medicine, and especially for cardiology. This text summarizes the discussions and opinions of a group of
investigators with a long-standing interest in this field. We addressed the occurrence of SCD in individuals apparently healthy, in patients
with heart disease and mild or severe cardiac dysfunction, and in those with genetically based arrhythmic diseases. Recognizing the need
for more accurate registries of the global and regional distribution of SCD in these different categories, we focused on the assessment of
risk for SCD in these four groups, looking at the significance of alterations in cardiac function, of signs of electrical instability identified by
ECG abnormalities or by autonomic tests, and of the progressive impact of genetic screening. Special attention was given to the identification
of areas of research more or less likely to provide useful information, and thereby more or less suitable for the investment of time and of
research funds.
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Translational Perspective
Sudden cardiac death (SCD) continues to be a major public health challenge, representing close to one-fifth of all mortality in industrialized
countries and making about half of its victims among people not previously diagnosed with heart disease. Currently, applied techniques of risk
assessment identifyonly a very small portion of all future cardiac arrests with sufficient specificity to justify defibrillator therapyand even in this
small subgroup medical and economic reasons call for improving the positive predictive value of our methods. Better information about the
incidence of SCD in different populations is urgently needed. Cardiovascular risk scores must be applied routinely in middle-aged persons and
research is necessary to determine which further tests are effective in people without cardiovascular symptoms when risk scores remain high
despite treatment. Integratedmodels for SCDriskmustbe developed and tested that combinevarious riskmarkers as identified for instance in
the ECG, in autonomic tests, in cardiac function tests and in genetic profiles, where progress is rapid.
Introduction
Death from cardiac disease has been diminishing in the industrialized
world during the last two decades.1– 4 Nevertheless, 20% of all
deaths still occur suddenly and unexpectedly, most often caused by
ventricular fibrillation (VF) or asystole. However, precise figures
are lacking for many regions of the world.5 It is estimated that
sudden cardiac death (SCD) claims 10 times as many lives as do
traffic accidents in the EU and USA combined, emphasizing the im-
portance of this societal challenge and of efforts to improve SCD
risk stratification.
Sudden cardiac death occurs in different population groups: (i) a
large subset without a prior diagnosis of heart disease; (ii) patients
with a history of heart disease with no or mild cardiac dysfunction;
(iii) patients with a history of heart disease and severe cardiac dys-
function; and (iv) those diagnosed with a defined genetically based
cause for a life-threatening cardiac arrhythmia (Table 1). The majority
of SCD victims is not known to have had heart disease, or have heart
disease with a normal or mildly impaired cardiac function (left ven-
tricular ejection fraction, LVEF .40%). Our ability to recognize
their risk before the event is severely limited. This raises the question
whether our methods for prediction of SCD can be improved now
and in the future, in order to develop appropriate preventive mea-
sures for this large number of potential victims.
In the following sections, we will consider how the risk of SCD can
be assessed in those without a history of cardiac disease, how signs of
electrical instability on the ECG may predict SCD, how results of
autonomic nervous system (ANS) tests may be used, how pump
function influences SCD risk and how genetic screening may help
predict SCD.
No previous history of cardiac disease
Between 45 and 50% of SCD victims are not previously diagnosed
with heart disease.6– 8 Most have coronary artery disease (CAD),
while at younger age cardiomyopathies and ion-channelopathies
play a major role in cardiac arrest and SCD. The risk of developing
a CAD substrate, or expression of a coronary event, can be assessed
by using risk scores (such as Framingham, or SCORE) based on age,
gender, smoking, blood pressure, total and LDL cholesterol, body
mass index, and diabetes.9,10 Some risk scores have added other
lipid measurements, socio-economic factors or a family history of
heart disease. It should be appreciated that the relation between
levels of LDL cholesterol or blood pressure and subsequent
cardiac events varies across countries.11 Therefore, SCORE provides
different tables for high- and low-risk countries in Europe.12 The
decision which risk calculator should be used has an important
impact on risk categorization and absolute risk estimation, with
broad implications for guidelines recommending therapies.13 More-
over, as time passes, it is likely that country-specific risk patterns
maychange, in parallelwith emerging socio-economic and healthcare
patterns.
On-line access has made these risk scores readily accessible for
physician and layman. Primary prevention of cardiovascular disease
using validated risk scores is possible, although questions remain
about the appropriate intensity of intervention in relation to the
level of risk.14,15 The parameters used in the current risk scores are
derived from population studies andhave limitedpower for individual
risk stratification, with possible exceptions in the highest risk sub-
groups such as diabetics who smoke and have high blood pressure
and LDL cholesterol levels (although having diabetes already puts
patients in the high or very high-risk category). Also, these risk
markers do not specifically predict SCD, but rather combined
cardiac events (Framingham) or cardiovascular mortality (SCORE).
At present risk scores can be used to identify subjects who are
most likely to achieve a statistical benefit from preventive medical
therapy12 and to motivate individuals to reduce correctable risk
factors. This emphasizes the need for public education initiatives
creating awareness of easily accessible risk assessment models on
the Internet. As a general approach a risk score should be routinely
performed around the age of 40 years in males and in post-
menopausal women,12 by a first line healthcare professional.
Repeat risk assessments are appropriate depending on the presence
and severity of risk markers.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 The different groups that contribute to the
total number of sudden cardiac deaths and our current
ability to identify possible candidates before the event
%of all SCD Predictability
Not diagnosed with heart disease 45 Poor
History of heart disease: LVEF
.40%
40 Limited
History of heart disease: LVEF
,40%
13 Possible
Genetically based arrhythmic
disease
2 Limited
SCD, sudden cardiac death; LVEF, left ventricular ejection fraction.
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The incremental value of a family history of heart disease or SCD
and biochemical and genetic markers reflecting atherosclerosis, co-
agulation, endothelial function, inflammation, oxidative stress, renal
function, neuro-humoral status, and cardiac pump function16 to
predict cardiovascular events, particularly SCD, needs to be evalu-
ated as a function of age, gender and ethnic background. Risk assess-
ment shouldbedynamic, repeatedover time.17 Therisk level atwhich
more advanced diagnostic methods should be performed in the
person without a history of heart disease needs to be better
defined in the context of clinical and economic efficacy.
The fact that most SCDs occur in individuals without a history of heart
disease emphasizes the importance of routinely using accepted risk
scores to identify people who will benefit from lifestyle improvement and
medical interventions, to motivate them to correct risk factors and to
refer them to a cardiologist for additional testing when corrective measures
are insufficient.
Electrical instability and sudden cardiac
death
A plethora of studies has examined the value of different ECG-
derived risk parameters, both in the general population18 and in
patients with different cardiac diseases. Their practical value is some-
times unclear because of small sample size or limited follow-up
duration, and studies determining which parameter combinations
provide strong risk predictors are lacking. Table 2 lists their availability
in the 12 lead ECG or Holter recording, and their reported value in
people without diagnosed heart disease or in the presence of heart
disease with either a preserved or diminished LVEF. When the abso-
lute risk is low, the predictive value of a single test will also be low,
although relative risks up to three have been reported for some para-
meters. Identification of the optimal combination of ECG risk
markers remains a challenge, realizing that some give information
about an arrhythmia substrate, and others about possible arrhythmia
triggers, neural influences, and genetic background.
Among a population without clinical evidence of cardiovascular
disease sinus rate at rest, during and after exercise or during mental
stress,19–22 have been helpful in recognizing SCD risk over a long
follow-up period. Risk was markedly elevated (Hazard Ratio
between 2 and 6) with a high resting heart rate (.75 b.p.m.), a
limited heart rate increase during exercise (,89 b.p.m.), or a sluggish
heart rate recovery (,25 b.p.m.). This was interpreted as an
impaired ability to increase not only vagal but also sympathetic
activity to appropriate levels.19
The usefulness of corrected QT interval (QTc) has been evaluated
in prospective cohort studies23 and in subjects .55 years of age a
prolonged QTc (.450 ms in men and .470 ms in women) was
associated with a three-fold increased risk of SCD.24 A prolonged
Tpeak–Tend interval measured in lead V5 seems independently
associated with SCD, even when the QTc is normal.25 In a study of
10 864middle-aged subjects fromFinland, prevalence andprognostic
significance of early repolarization in the inferior/lateral leads of the
12-lead ECG over a mean follow-up of 30 years was determined.26
When stratified according to the degree of J-point elevation
(≥0.2 mV) in inferior and/or lateral leads, there was a three-fold
higher risk for both death from cardiac causes and from arrhythmias.
In the same database, T-wave inversions, wide QRS-T angle, and
prolonged QRS duration due to either left bundle branch block
(LBBB) or intraventricular conduction delay but not right bundle
branch block, predicted SCD. In similar studies of general population
samples27–29 essentially the same ECG variables predicted all-cause
mortality and also SCD,18 yet none of them usefully predicts individ-
ual risk.
In patients with cardiovascular disease but preserved LV function,
several ECG parameters predict the occurrence of cardiac death.
This patient group is of particular importance as it generates 30–
40% of all SCDs. In particular, heart rate turbulence (HRT) and decel-
eration capacity were shown to select patients with preserved LV
function who have similarly high risk of SCD as those with
depressed LV function.30 In the combined Finnish and German
database of survivors of acute myocardial infarction (AMI), non-
sustained ventricular tachycardia (VT) and several measures of
heart rate variability predicted SCD among those with preserved
left ventricular function.31 However, none of these variables was
associated specifically with the occurrence of SCD since they
were stronger predictors of non-SCD. Similarly, microvolt
T-wave alternans (MTWA) carries prognostic value in patients
with preserved LV function,32 but results cannot be obtained in a
large group that does not show the required heart rate increase
or is in atrial fibrillation. Based on these and similar studies, the
REFINE-implantable cardioverter-defibrillator (ICD) trial is cur-
rently randomizing infarct survivors with a LVEF between 36 and
49%, reduced HRT and positive MTWA to standard therapy or
the ICD.
In patients with cardiovascular disease and impaired LV function
parameters such as QRS duration, particularly in the presence of
LBBB, HRT, baroreflex sensitivity (BRS), or T-wave alternans are
independently associated with increased risk for SCD. The latter
may have a particularly high negative predictive value potentially
useful in selecting patients unlikely to benefit from device
therapy.32
There are limitations of current ECG-derived risk predictors. For
instance, some of the more promising methodologies such as HRT or
MTWA assessment cannot be applied to patients in atrial fibrillation
(which by itself is a risk predictor for SCD). The REFINE and
CARISMA33 trials have demonstrated that risk stratification in
patients after an acute ischaemic event should be done 6–8 weeks
later as tests performed earlier lack strong predictive power, likely
due to the fact that there is remodelling of the arrhythmogenic sub-
strate during the early weeks after myocardial infarction. However,
this may not apply to autonomic parameters, as demonstrated by
the validity of risk stratification performed by BRS assessed 2–3
weeks post-MI in ATRAMI and by similarly early assessment of
HRT and deceleration capacity.30,34 Finally, there is a lack of
dynamic risk assessment studies over time.17 At present, it remains
largely unknown for which time interval a given risk assessment will
optimally predict individual risk for SCD.
In patients with genetically based causes for lethal arrhythmias, the
evidence thatECG parameters are helpful in risk stratification is clear,
particularly for the long QT syndrome (LQTS), and partially for the
Brugada syndrome. This is well established for the magnitude of
QT interval prolongation,35 whereas the evidence of a risk predictive
role for heart rate is more recent and limited to specific genetic
subgroups.36
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To prospectively determine the best risk score using ECG parameters,
listed in Table 2 for the four groups from Table 1, remains a challenge. It
seems that static, ECG-based parameters as well as dynamic metrics of
RR interval patterns, and of ventricular repolarization can be useful for risk
stratification in all groups. Further research is needed into the dynamic behav-
iour of parameters and into the predictive power of parameter combinations.
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Table 2 ECG-derived risk stratifiers reported to have prognostic value in different clinical settings
No HD diagnosis preLVEF redLVEF 12-lead ECG Holter
Sinus rhythm
Resting rate, profile during exercise tolerance test + + ? + +
Heart rate variability +/2 + + 2 +
Heart rate turbulence ? + + 2 +
Deceleration capacity ? + + 2 +
Intra-atrial conduction delay + + + + 2
Atrial dilatation + + + + 2
Atrial fibrillation + + + + +
AV conduction
Site of AV block + + + + +
Presence of accessory AV pathways + ? ? + +
QRS
Width .100 ms ? + + + +
Left bundle branch block + + + + 2
Notching, fractionation ? + + + 2
Number and location of Q waves ? + + + 2
Reduced voltage (limb leads) ? + + + 2
Signal-averaged ECG ? + + + +
Left ventricular hypertrophy + + + + 2
Mean QRS—T angle + + + + 2
QT interval
Duration + + + + +
Dispersion ? + + + 2
Dynamicity ? + + 2 +
ST segment
Elevation/depression +/2 ? ? + 2
Early repolarization (infero-lateral leads) + ? ? + 2
T-wave
Axis + + + + 2
Negativity + + + + +
T-wave alternans ? + + 2 +
Tpeak–Tend interval in V5 ? + + + 2
T amplitude V1 and aVR + ? ? + 2
Ventricular ectopy
Width and site of origin + + + + +/2
VPB coupling interval +/2 + + + +
Frequent VPBs +/2 + + + +
Increase during exercise + + + 2 +
Non-sustained VT 2 + + 2 +
Sustained VT ? + + 2 +
No HD DIAGN, no diagnosis of heart disease; LVEF, left ventricular ejection fraction; preLVEF, cardiac disease, preserved LVEF; redLVEF, cardiac disease, reduced LVEF; VPB,
ventricular premature beat. The majority of these parameters has been shown to predict mortality, not specifically SCD.
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Risk prediction based on autonomic
abnormalities
The ANS helps maintain body homoeostasis. Autonomic nervous
systemabnormalitiesmay becauseddirectly byautoimmune diseases
and metabolic neuropathies, such as diabetes mellitus,37,38 or indir-
ectly by the ANS response to disturbed homoeostasis, as in congest-
ive heart failure (HF).39 Autonomic nervous system imbalance may
cause clinically relevant perturbations in cardiac physiology. In
cardiac patients, the strength of the association between ANS abnor-
malities, poor outcome, and cause-specific mortality, namely SCD,
likely depends upon the underlying cardiac condition and upon the
presence of diabetes or renal insufficiency.40 Although obviously im-
portant, genetic predisposition to ANS abnormalities is still poorly
understood. Experimental and clinical data show that enhanced para-
sympathetic influence on the heart is generally antiarrhythmic and
antifibrillatory41,42 while increased sympathetic influence is generally
pro-arrhythmic.42– 44 In particular, sympathetic dominance com-
bined with other pro-arrhythmic processes such as myocardial is-
chaemia leads to increased probability of VF and thus SCD risk.43
Specific autonomic tests distinguishing the risk of arrhythmic vs. asys-
tolic SCD are desirable but not developed.
Autonomic tests45 include recording and analysis of spontaneous
RR intervals, simple or complex provocations such as the Valsalva
manoeuvre, handgrip test, cold face test, carotid massage, neck
suction, low body pressure test, and baroreflex testing. While ex-
ploring different reflexes, involving different aspects of autonomic
modulation, all of them measure RR interval and blood pressure
responses.
Clinical exploration of autonomic markers for SCD risk stratifica-
tion has been largely obtained from studies involving autonomic
modulation of RR interval changes following either provoked or
spontaneously occurring blood pressure changes to assess barore-
flex responsiveness,46,47 and has been fostered mainly by pioneering
studies of BRS in a conscious post-MI canine model for SCD.48
A particularly powerful risk prediction for cardiac death and life-
threatening arrhythmias in ischaemic heart disease and HF has
been obtained with BRS48–51 and with tests separating the sympa-
thetic and vagal control of sinus node activity, such as with HRT
and deceleration capacity.30,52,53 Autonomic nervous system func-
tion can also be assessed from heart rate responses to exercise
testing. Heart rate recovery after exercise has prognostic significance
for both total and sudden cardiac mortality.54,55
Validated models of spectral analysis of RR intervals permit asses-
sing the strength of cardiac sympathetic and vagal modulations, espe-
cially when measuring responses to well-defined provocations.56,57
The environmental data stability and accuracy of the analyses, includ-
ing rejection of ectopic beats, are essential in such studies.
Despite the largenumberof existingANS function tests, little com-
parative data exist regarding their predictive value. No guidance
exists to which ANS test or combination of tests is most appropriate
in different clinical conditions. Advanced age decreases but not elim-
inates the value of ANS tests in predicting poor outcome, as shown
with baroreflex testing in elderly post-MI patients.58 Autonomic
nervous system tests are not influenced by usual clinical doses of
beta-blockers,52,59 whereas sleep abnormalities affect autonomic
testing based on full 24-h data.60
A consensus exists that the risk prediction power of ANS
tests increases when quantifying autonomic responses to specific
provocations rather than studying unprovoked baseline ANS func-
tion. Not only the provocations underlying a test but also its environ-
mental conditions must be standardized: while the predictive power
of 24-h RR interval variability in hospitalized cardiac patients has been
well documented, similar analysis of recordings in truly ambulating
out-of-hospital patients is of little value because of the differences
in environmental challenges to which the ANS responds. Short-
duration tests should become the standard for ANS testing in
cardiac patients for risk prediction.61,62 For studies of RR interval
dynamicity, a combination of sufficiently long-resting period (e.g.
20–30 min) with a strictly standardized staged exercise test (includ-
ing its recovery phase or tilting) might prove useful,63,64 as well as tilt
or simple postural provocations.
Autonomic nervous system-based risk assessment has been
attempted in patients without cardiovascular disease but its predict-
ive value is likely too low to make such studies useful for first line SCD
risk-screening.
The predictive value of ANS testing in cardiac patients appears in-
dependent of ventricular function65 and can be thus used in patients
with and without compromised LVEF.30,46 Tests involving RR interval
measurements (either alone or in combination with blood pressure
measurements), however, require normal sinus node function.
Indices of the QT interval variability and other ventricular repolar-
ization markers may allow investigating ANS influence at the ven-
tricular level and can be used to quantify autonomic function66– 68
providing information probably complementary to that derived
from heart rate variability. The measurement of QT variability,
alone or simultaneously with RR variability, may improve risk stratifi-
cation in patients with life-threatening arrhythmic diseases, specific-
ally those with the LQTS.69
Autonomic nervous system-based risk assessment in patients with
genetically based cardiac diseases is in its infancy but preliminary
encouraging data are being obtained. Hyperreactive ANS reflexes
leading to very abrupt RR interval changes in either direction
appear to pose an increased risk in those LQTS patients (LQT1)
whose genetic mutations impair the IKs current and who are
thereby unable to appropriately adapt their QT interval to abrupt
heart rate changes.70 This is an example of how ANS responses
may dangerously interact with underlying genetic abnormalities.
Regional abnormalities in cardiac sympathetic innervation are
associated with increased arrhythmic risk and they can be quanti-
fied by imaging techniques. Recently, the 123-I MIBG defect score
was found to independently predict ventricular arrhythmias
causing appropriate ICD shocks.71 The combination of traditional
markers of ANS activity with imaging techniques quantifying the
degree of sympathetic denervation at ventricular level appears
promising.
Autonomic nervous systemmarkers contribute to SCD risk stratification.
Arrhythmic risk is enhanced whenevermarkers of vagal activity decrease or
markers of sympathetic activity increase. Both RR and QT variability may
provide useful and complementary information. Reflex autonomic
responses are more informative than baseline measurements. The
limited use of ANS tests is partially due to their complexity. Analyses
derived from tests as simple as an exercise stress test are more likely to
impact on clinical practice.
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Role of cardiac function
Left ventricular function as reflected by ejection fraction, as well as
functional capacity, expressed by a variety of parameters (NYHA
class, maximum oxygen uptake, and exercise duration) are directly
related to both total mortality and SCD in patients with heart
disease. As such, LVEF has been used as a primary entry criterion
for multiple clinical trials. In addition, NYHA functional class has
been added to LVEF as an entry criterion in trials of SCD in patients
with HF. Easy to measure, but with significant errors depending on
the method used, LVEF now occupies a central position in guidelines
for use of ICDs when recommended for primary prevention of SCD.
The rationale is that LVEF significantly modifies the effects of all other
variables that impact on both total mortality and SCD risk. However,
there are multiple limitations to the use of LVEF as the sole determin-
ant of high risk and, therefore, as indication for ICD: (i) the population
with HF and reduced (,30 or 35%) LVEF (HFrLVEF) accounts for
,20% of all SCDs;8,72 (ii) there is no evidence that LVEF bears a
direct causal relation to arrhythmia mechanisms; (iii) LVEF exhibits
considerable spontaneous variability in some individuals; (iv) meas-
urement of LVEF in practice is often less than precise. Furthermore,
recent data indicate that most of SCD victims did not havea previous-
ly documented depressed LVEF, and would have not been candidates
for ICD therapy.73,74
Among survivors of AMI whether in the pre- or post-reperfusion
era,75 low LVEF (cutoffs 30–40%) has accounted for 22–72% of SCD
cases. The relation between LVEF and mode of death (SCD vs.
non-SCD) in patients with CAD shows no significant difference in
per cent of SCD for any range of LVEF.8 Similar findings characterize
patients with HF in the CHARM programme.76 Thus, LVEF lacks both
sensitivity and specificity for prediction of SCD risk.77,78
Multiple factors other than LVEF and NYHA class, and their inter-
action, may contribute useful information towards prediction of
SCD risk. Another important caveat is that not all SCDs are due to
arrhythmia. Non-arrhythmic causes are found by autopsy in 50% of
SCD cases in patients with recent MI, and there is autopsy evidence
of acute coronary events in 54% of SCD cases with CAD and even in
5% of SCD cases in patients without CAD.79 In 97% of cases, the AMI
was not diagnosed clinically ante-mortem. Of interest in relation to
the diagnostic accuracy of autopsy is that post-mortem MRI results
in a higher diagnosis of peracute infarction as possible cause of
SCD.80 This also indicates the feasibility of a post-mortem MRI in
the absence of consent for clinical autopsy. Also the severity of HF,
as judged by NYHA class, does not correlate with mode of death if
one examines only patients with LVEF ≤40%.81 However, the rela-
tive incidence of SCD ( vs. death due to progressive HF) in patients
with HF and preserved LVEF (HFpLVEF) is roughly half of that in
patients with HF and reduced LVEF (HFrLVEF).82,83 In contrast, the
CHARMstudies showednosignificantdifference in relative incidence
of SCD vs. progressive HF death for patients with HFpLVEF vs.
HFrLVEF.76 On balance, it appears that total mortality and SCD
rates are somewhat lower in patients with HFpLVEF than in patients
with HFrLVEF.84
Other demographic characteristics of SCD are also important
to place the relative importance of HF in perspective. In the Maas-
tricht prospective registry, only 26% of SCD cases had a history
of HF.72,74 The underlying cause of HF (coronary vs. non-CAD
cardiomyopathy) influences mechanisms of arrhythmias, and mortal-
ity risk, with most studies finding significantly higher mortality in
patients with CAD.85 Unfortunately, although approximately 50%
of SCDs occur in persons with HF and an LVEF .35%, there are
little data in this group and no variables have proved useful to identify
individuals at increased risk specifically for SCD.82,86– 88 However,
several small studies of patients with recent AMI and LVEF .35–
40% have reported results that suggest potential utility for risk strati-
fication for mortality and possibly SCD using additional diagnostic
tests such as T-wave alternans,89 BRS,46 and HRT.90
Predictors of SCD in patients with HFrLVEF have been sought for
years. Single risk factors in this population have limited utility, while
analysis of multiple risk factors performs far better for prediction
of total mortality and SCD, as it happens in patients with CAD.91
The most widely used model is the Seattle Heart Failure Model.
This algorithm uses multiple readily available clinical variables to
predict mortality.92 Retrospectively applied to a large population
of patients enrolled in six clinical trials of pharmacological HF
therapy,93 it did identify patients at increased risk for total mortality
but it had limited accuracy to predict SCD.
Of interest is the emergence of biochemical markers as potential
risk stratifiers in patients with HF or CAD. A number of studies eval-
uated the relation between BNP and/or N-terminal of the prohor-
mone brain natriuretic peptide (NTproBNP) and SCD in both HF
populations and post-MI patients94,95 and noted significant associa-
tions between BNP and SCD or ventricular arrhythmias detected
by ICD.96 Of note, a retrospective analysis of patients who had
received ICDs for primary preventionof SCD found not only a signifi-
cant association between NTproBNP and appropriate ICD therap-
ies, but patients with higher levels of BNP had a significantly higher
increase in their risk for appropriate ICD intervention than in their
mortality risk.96 This suggests BNP may have utility in identifying
patients specifically at risk for SCD and sustained VT. Other bio-
chemical markers being actively investigated for utility in risk stratifi-
cation of HF or post-MI patients include markers of collagen
turnover, and C-reactive protein.97 There is far less clinical experi-
ence with these markers than BNP, and more data are needed
before their potential role is clear.
In view of our current inaccurate SCD prediction, apart from LVEF and
NYHA class, the role of other factors needs to be evaluated
prospectively. This holds both for the HF patient with reduced or preserved
LVEF.
Role of genetics
Genetic screeninghas thepotential of contributing significantly to the
identification of individuals at greater risk for SCD. A few concepts
need clarification before examining its role in genetically based
disorders, in myocardial ischaemia-related SCD, and in the general
population.
Genetic variants may be rare (,1 in 1000), common (. 1 in 100),
or of intermediate frequency. The greatest disease effect is caused by
rare variants (mutations), whereas the common ones (single nucleo-
tide polymorphisms, SNPs) have been associated with modest
or minimal effects. Genetically based disorders—such as LQTS,
Brugada syndrome, and catecholaminergic polymorphic VT—are
due to disease-causing mutations, whereas in complex diseases (MI
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and CHF) an interaction likely takes place between the arrhythmo-
genic substrate (scar and dilated ventricles) and several SNPs, each
contributing to a decrease or increase in cardiac electrical stability.
These relatively common genetic variants capable of modifying the
propensity to life-threatening arrhythmias are referred to as ‘modi-
fier genes’. Their effects may help understanding why patients with
the same disease and similar clinical parameters may either survive
long term or die suddenly.
Genetic variants are not immutable. There is growing evidence,
encompassed by epigenetics, that environmental factors (age, food,
pollution, and radiation) may modify clinical expression of SNPs. A
critical concept is that of the algebraic summation of different
SNPs. Each SNP has, by definition, a small effect and is thus unlikely
to play a major role by itself. The number of SNPs potentially inter-
acting with either the disease-causing mutation or with the arrhyth-
mogenic substrate is large, however, and a cumulative effect must
be expected. Protective and arrhythmogenic SNPs may annul each
other but if an individual inherits a series of SNPs acting predominant-
ly in one direction, there may be an important effect on clinical
outcome (Figure 1), and initial examples have been published.98
This cumulative effect, depending on which SNPs are inherited,
represents the unpredictable play of chance. The progressive identi-
fication of SNPs acting on cardiac electrical stability will allow to
significantly refine risk stratification by the use of ‘clusters of SNPs’.
This should be an area of expanding research.
Two additional concepts are relevant. The probability of identify-
ing modifier genes increases whenever the disease-causing mutation
is the same in the population under study, as it happens in the
so-called ‘founder populations’, because this approach corrects for
the different effects produced by different individual mutations.99
Also, research in this field must deal with clean phenotypes. Regard-
ing SCD, this requires that the population studied must be at risk of
dying because of a primary lethal arrhythmia related to a single
trigger (e.g. acute myocardial ischaemia) and not as a consequence
of VF resulting from progressively worsening cardiac function.
Based upon this conceptual foundation, we can discuss where we
stand and where we should go for a more fruitful approach to risk
stratification for SCD.
Long QT syndrome, with 80–85% success in positive genotyping,
is the best understood among the genetically based channelopa-
thies100 and serves as an appropriate paradigm for SCD. Risk stratifi-
cation in LQTS has progressively incorporated clinical parameters
(e.g. previous occurrence of syncope, QTc .500 ms), specific
genetic subgroups (LQT1 vs. LQT2 vs. LQT3), the mutation site
(e.g. transmembrane vs. C-terminal), the type of mutation (missense
vs. non-missense), the biophysical function (dominant negative vs.
Figure 1 Illustration of the potential impact on outcome (survival vs. sudden death) of the interaction between two arrhythmogenic substrates
(acute myocardial infarction or heart failure, and mutations causing arrhythmogenic diseases) and predominantly protecting or damaging clusters of
common genetic variants (SNPs). As the cluster of SNPs of a given individual reflects the inheritance by the parents, this interaction is clearly gov-
erned by chance.
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haploinsufficiency), and mutation-specific consequences. The focus
is now on the interaction between the disease-causing mutations
and the SNPs which have already been found to modify the arrhyth-
mic risk. Most of them increase risk,101 and sometimes QT interval
duration, but recently also ‘protective’ SNPs have been recog-
nized.102,103 This is a critically important area of research because
of its implications for individual risk prediction, both for the inherited
channelopathies and SCD generally.
Although a strong genetic component exists in the risk for SCD,
typically occurring in individuals over 40 years with cardiac ischaemia
or infarction,104– 108 the underlying genetic variation remains un-
known. Key barriers to the identification of these genetic factors
have been restricted sample sizes, heterogeneity of the associated
cardiac substrate, and the difficulty of ascertaining adequate pheno-
type information after cardiac arrest.109 Especially heterogeneity of
the substrate hampers successful gene finding in population sample
studies as within every individual substrate the interplay of many
different pro-arrhythmic factors involves too many potentially
causative genes.110 By contrast, VF in the setting of a first AMI is
most likely based on re-entry and as such has one underlying arr-
hythmogenic mechanism. To date, four genome-wide association
studies (GWAS) on VF/SCD have been published111 –114 and one
of the two SNPs that were identified in GWAS studies comes from
AGNES, a study in patients with and without VF in the setting of a
first AMI.111 A stark contrast is represented by studies based on
mixed phenotypes as in ICD patients using appropriate shocks as
endpoint.115 – 117 Such patients are at risk of VF through many differ-
ent mechanisms (pump failure in a scarred ventricle, different medi-
cations, electrolyte disorders, etc.) and the hope to identify single
genetic variants predicting SCD in these populations is probably
naive. Future research and funding should go for studies with a
clean phenotype and a homogeneous underlying arrhythmia mech-
anism likely to provide the highest yield.
An alternative approach to unravel the genetic basis of SCD is to
identify genetic variants associated with phenotypes that are consid-
ered as risk factors for SCD, i.e. ‘intermediate phenotypes’, such as
heart rate, QRS width, and QT interval. Genome-wide association
studies have identified numerous ‘hits’,110 but attempts to link
them to SCD have so far not been successful.112,117,118
Genetic screening has a high potential to contribute to the identification
of individuals at risk for SCD, as has already been proved for genetically
based diseases. There is a strong rationale for expecting significant insights
also for SCD in the general population but this will require studying homo-
geneous phenotypes. The use of novel technologies including next gener-
ation sequencing119 and the smart analysis of clusters of common
genetic variants, as risk modifiers, hold significant promise.
Conclusions and recommendations
Both national and regional SCD registries are needed with data about
medical history, gender, and race. They must allow the evaluation of
the effects of different measures taken to reduce out of hospital
cardiac arrest mortality to increase insight of their value.
For the population without a history of heart disease, more atten-
tion should be given to public education initiatives, addressing aware-
ness of risk for development of coronary disease as a cause of early
death, including SCD.
Primary healthcare providers should be strongly encouraged to
apply risk scores routinely, both in men over 40 years of age and in
women after the onset of menopause. There is also need for a com-
parison of the value of the different risk score methods. The esti-
mated level of risk can be used in a dynamic way17 to determine
whether and when advanced diagnostics are appropriate. The incre-
mental value of bio- and genetic markers reflecting atherosclerosis,
coagulation, inflammation, neuro-humoral status, and ventricular
function requires evaluation in this population, in the context of
clinical and cost efficiency.
Current guidelines recommend 12-lead ECG screening for certain
high-risk occupations and for professional athletes, but not for all
asymptomatic middle-aged subjects. Since many of ECG indexes
have the potential to identify future arrhythmic death, the utility of
routinescreeningof the12-leadECGshouldbeexplored fromexisting
databases, especially considering value and cost of analysing a 12-lead
ECG in addition to a standard risk score. The main rationale of this
approach is the identification of subclinical cardiac disease, such as
asymptomatic myocardial infarction, left ventricular hypertrophy,
and fibrosis, which are common autopsy observations in victims of
SCD even in the absence of previously diagnosed cardiac disease.
Inpatientswith cardiac diseaseandpreservedor reducedventricu-
lar function, we need large registries and randomized trials to deter-
mine the value of ECG markers for risk assessment.
Autonomic balance affects the cardiac response to acute challenges
such as ischaemia or tachyarrhythmia, thus importantly influencing
outcome. The large number of proposed tests and the inability to
standardize acquisition and analysis of parameters have contributed
topreventing ANS-based testsbecoming routinelyused for theclinical
assessment of SCD risk. This is unfortunate because some tests, espe-
cially those quantitating reflex responses, are of proven value. Future
approaches should focus on well-standardized tests that are easily
obtained and can be readily interpreted. Long-term ambulatory mon-
itoring no longer represents a favoured approach for ANS assessment.
Autonomic responses during exercise testing or other provocative
manoeuvers under standardized circumstances will likely provide
optimal information but this requires prospective evaluation.
Measurement of resting systolic function (LVEF) and assessment of
clinical severity of HF (NYHA Class) are the only risk stratifiers cur-
rently in widespread use. While they are good predictors of total mor-
tality, their sensitivity and specificity for prediction of SCD is not
adequate. Current practice guidelines for implantation of ICDs for
primary prevention of SCD, based on these parameters, have demon-
strated their clinical and cost-effectiveness but they do not impact the
majority of patients who will die suddenly as a first cardiac event or
during the onset of AMI.74,120 Apart from LVEF and NYHA Class,
many other factors are probably important for the SCD risk profile,
such as age, gender, ethnicity, blood pressure and heart rate, ischaemic
vs. non-ischaemic cause, diabetes, kidney function, as well as findings
during cardiac imaging, electrical instability, ANS balance, biochemical
markers, and the genetic profile. Whether the significance of these
factors is affected by treatment and by time needs to be evaluated.
At present, there is scant information about SCD risk in patients
with HFpLVEF. Newer functional markers of pump failure, such as
BNP, show promise as indicators of SCD risk, but prospectively well-
designed clinical trials evaluating their ability to guide ICD therapy are
needed, before they can be recommended.
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While individual risk markers often lack the power to influence
clinical practice, it seems important to investigate integrated risk
models, combining parameters that characterize properties of the
arrhythmia substrate, the triggers and the ANS.
The genetic variants, identified thus far either as modulators of
ECG traits or of SCD, have proved useful for genetically based
diseases such as LQTS, but are not ready to be used clinically
for assessing genetic susceptibility to SCD in the general popula-
tion. Yet, genetic factors can contribute significantly to this huge
health problem. The areas where research should expand, for
further refinement of risk stratification, include the use of clusters
of relatively common or even rare genetic variants (SNPs)
capable of increasing or decreasing the risk for SCD associated
either to a disease-causing mutation or to an arrhythmogenic
substrate.
Worldwide collaboration is needed in order to increase sample
sizes and consequently statistical power for detecting more variants.
Currently, the published efforts to gain statistical power have been at
the expense of phenotypic homogeneity (unexplained SCD in the
community or post-MI ICD patients). Instead, to further the field it
will probably be ideal to use whole exome or whole genome sequen-
cing in large cohorts with a clean phenotype associated with SCD,
possibly through just one or two well-defined arrhythmogenic
mechanisms.
When designing prognostic models for assessing SCD risk or clin-
ical studies for demonstrating ICD benefit, it is important to consider
that risk factors may change over time and that patients may be at a
substantial risk of dying from other causes than the one intended
to be treated. Modern statistical techniques such as time-dependent
covariates in Cox proportional hazards models and cause-specific
hazard (competing risks) modelling must be used to address such
challenges in risk stratification.
Table 3 summarizes the currently recommended approach to SCD
risk stratification as well as our suggestions for areas of research. We
feel that better methods for identification of high SCD risk are espe-
cially needed following AMI, either by combining presently available
risk markers or by developing new ones. Genetic studies already pro-
vided markers for arrhythmia risk but thus far only in small subgroups
of the population.
It is obvious that we still have a lot to learn on how to make a de-
pendable risk profile for individual patients. When realizing our
current inability to identify most cardiac arrest victims before the
event, we should also consider the development of better strategies
to improve results of SCD resuscitation attempts. This will require
public education and training, better emergency response systems,
and probably the development of minimally invasive devices that
upon detection of VF sound an audible alarm and provide the
victim’s location to emergency services.121 Meanwhile, progress
Table 3 Our current approach to sudden cardiac death risk stratification and areas for research
Based on what we know today
No diagnosis of cardiovascular disease Assess CV-risk factors in men .40 and women after menopause;
correct risk factors. Give advice about lifestyle;
when corrective measures remain insufficient, refer to cardiologist for additional testing
History of heart disease, no or mild dysfunction Determine anatomic and functional cardiac status (Echo and LVEF);
check ECG for abnormalities; exercise stress test;
correct cardiac ischaemia and other risk factors.
History of heart disease, reduced LV function Determine anatomic and functional cardiac status (Echo, LVEF, and MRI);
check ECG for abnormalities;
correct cardiac ischaemia, risk factors and HF;
NTproBNP;
determine indication for ICD and resynchronization;
FOLLOW the GUIDELINES
Genetically based pro-arrhythmic disorders Genetic work-up based upon phenotype;
genetic evaluation of the family of the proband;
FOLLOW the GUIDELINES
What we recommend for research
In general Registries collecting ALL SCDs per year per region with data about medical history, gender,
and race;
value of ‘old’ risk markers in current reperfusion practice;
long-term prospective studies of current and new risk markers;
develop and implement systems to improve resuscitation
No diagnosis of cardiovascular disease Study value of adding biomarkers and genetic markers to present risk scores
History of heart disease, no or mild dysfunction Study value of adding biomarkers to present risk scores
prospectively determine the best combination of ECG-derived risk stratifiers
History of heart disease, reduced LV function Study value of adding biomarkers to present risk scores
prospectively determine the best combination of ECG-derived risk stratifiers
improve patient selection for ICD implant and cardiac resynchronization
study value of MRI for arrhythmic risk stratification
Genetically based pro-arrhythmic disorders Further define different phenotypes, improve risk stratification, knowledge of modifiers, and
gene therapy
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will also continue to depend on the willingness of governments
worldwide, through their funding agencies, as well as philanthropic
foundations and interested corporate sectors, to accelerate a
well-focused effort in this direction.
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